Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin’s lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma primarily affects older patients and is frequently chemotherapy-resistant, which has further fostered the necessity for new, chemotherapy-free treatment options. In the past decade, targeted therapies in mantle cell lymphoma have been practice-changing as the treatment paradigm shifts further away from relying primarily on cytotoxic agents. Here, we will review the pathophysiology of mantle cell lymphoma and discuss the emergence of targeted, chemotherapy-free treatments aimed at disrupting the abnormal biology driving its lymphomagenesis. Treatments targeting the constitutive activation of NF-kB, Bruton’s Tyrosine Kinase signaling, and anti-apoptosis will be the primary focus as we discuss their clinical data and toxicities. Our review will also focus primarily on the emergence and use of targeted therapies in the relapsed/refractory setting but will also discuss the emergence of their use in front-line therapy and in combination with other agents.
套细胞淋巴瘤（MCL）是一种罕见且异质性的B细胞非霍奇金淋巴瘤。标准一线治疗方案通常采用化疗，随后常辅以自体造血干细胞移植进行巩固治疗；然而，多数患者仍会出现淋巴瘤复发并需接受后续治疗。此外，套细胞淋巴瘤主要累及老年患者，且常对化疗产生耐药性，这进一步凸显了开发新型无化疗治疗方案的迫切需求。过去十年间，随着治疗模式逐渐摆脱对细胞毒性药物的主要依赖，靶向治疗已彻底改变了套细胞淋巴瘤的临床实践。本文将综述套细胞淋巴瘤的病理生理机制，重点探讨旨在阻断其淋巴瘤发生异常生物学过程的靶向无化疗治疗策略。我们将聚焦于针对NF-kB持续激活、布鲁顿酪氨酸激酶信号通路及抗凋亡机制的靶向治疗，系统分析其临床数据与毒性特征。本综述将主要探讨复发/难治性套细胞淋巴瘤中靶向治疗的发展与应用，同时对其在一线治疗及联合治疗方案中的新兴应用进行评述。
肿瘤(癌症)患者之家